WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H530551
CAS#: 58-60-6
Description: Puromycin Aminonucleoside, also known as PAN, NSC3056, is useful in the study of human glomerular disease, and glomerular function and morphology. PAN is used to probe endothelial glycosaminoglycan synthesis in cultured glomerular endothelial cells and their relation to cell permeability.PAN treatment increased oxidative stress level of podocytes significantly with the induction of Nox4. Puromycin aminonucleoside increases podocyte permeability by modulating ZO-1 in an oxidative stress-dependent manner.
Hodoodo Cat#: H530551
Name: Puromycin Aminonucleoside
CAS#: 58-60-6
Chemical Formula: C12H18N6O3
Exact Mass: 294.14
Molecular Weight: 294.320
Elemental Analysis: C, 48.97; H, 6.16; N, 28.56; O, 16.31
Synonym: Puromycin Aminonucleoside; ARDMA; NSC 3056; SAN; Stylomycin aminonucleoside.
IUPAC/Chemical Name: (2R,3R,4S,5S)-4-amino-2-(6-(dimethylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3-ol
InChi Key: RYSMHWILUNYBFW-GRIPGOBMSA-N
InChi Code: InChI=1S/C12H18N6O3/c1-17(2)10-8-11(15-4-14-10)18(5-16-8)12-9(20)7(13)6(3-19)21-12/h4-7,9,12,19-20H,3,13H2,1-2H3/t6-,7-,9-,12-/m1/s1
SMILES Code: O[C@H]([C@@H]1N)[C@@H](O[C@@H]1CO)N2C(N=CN=C3N(C)C)=C3N=C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO and water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: Puromycin aminonucleoside (PAN)-induced nephrosis is a widely studied animal model of human idiopathic nephrotic syndrome because PAN injection into rats results in increased glomerular permeability with the characteristic ultrastructural changes in podocytes similar to human nephrosis.
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 294.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Fukuda H, Hidaka T, Takagi-Akiba M, Ichimura K, Oliva Trejo JA, Sasaki Y, Wang J, Sakai T, Asanuma K, Tomino Y. Podocin is translocated to cytoplasm in puromycin aminonucleoside nephrosis rats and in poor-prognosis patients with IgA nephropathy. Cell Tissue Res. 2015 May;360(2):391-400. doi: 10.1007/s00441-014-2100-9. PubMed PMID: 25676004; PubMed Central PMCID: PMC4544490.
2: Ha TS, Park HY, Seong SB, Ahn HY. Puromycin aminonucleoside increases podocyte permeability by modulating ZO-1 in an oxidative stress-dependent manner. Exp Cell Res. 2016 Jan 1;340(1):139-49. doi: 10.1016/j.yexcr.2015.12.001. PubMed PMID: 26683996.
3: Kakimoto T, Okada K, Fujitaka K, Nishio M, Kato T, Fukunari A, Utsumi H. Quantitative analysis of markers of podocyte injury in the rat puromycin aminonucleoside nephropathy model. Exp Toxicol Pathol. 2015 Feb;67(2):171-7. doi: 10.1016/j.etp.2014.11.007. PubMed PMID: 25481214.
4: Petrovic-Djergovic D, Popovic M, Chittiprol S, Cortado H, Ransom RF, Partida-Sánchez S. CXCL10 induces the recruitment of monocyte-derived macrophages into kidney, which aggravate puromycin aminonucleoside nephrosis. Clin Exp Immunol. 2015 May;180(2):305-15. doi: 10.1111/cei.12579. PubMed PMID: 25561167; PubMed Central PMCID: PMC4408165.
5: Yu L, Liu Y, Wu Y, Liu Q, Feng J, Gu X, Xiong Y, Fan Q, Ye J. Smad3/Nox4-mediated mitochondrial dysfunction plays a crucial role in puromycin aminonucleoside-induced podocyte damage. Cell Signal. 2014 Dec;26(12):2979-91. doi: 10.1016/j.cellsig.2014.08.030. PubMed PMID: 25229402.
6: Kang YL, Saleem MA, Chan KW, Yung BY, Law HK. The cytoprotective role of autophagy in puromycin aminonucleoside treated human podocytes. Biochem Biophys Res Commun. 2014 Jan 10;443(2):628-34. doi: 10.1016/j.bbrc.2013.12.015. PubMed PMID: 24333414.
7: Qiu WW, Yuan J, Yang L. [Effect of Wenyang Huoxue Lishul Recipe Containing Serum on Expression of Cathepsin L in Puromycin Aminonucleoside-induced Injury of Mouse Glomerular Podocytes]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2016 May;36(5):602-7. Chinese. PubMed PMID: 27386655.
8: Feng Z, Liu S, Shi W, Xiao H, Liang X, Liu X, Ye Z, Wang S, Liang Y, Zhang B, Wang W, Liu Y, Mei P, Xu L, Ma J, Xia Y. [Renal expression of RANK-RANKL in a rat model of puromycin aminonucleoside nephropathy]. Nan Fang Yi Ke Da Xue Xue Bao. 2014 Jan;34(1):65-9. Chinese. PubMed PMID: 24463119.
9: Xie H, Lin HL, Wang N, Sun YL, Kan Y, Guo H, Chen JL, Fang M. Inhibition of microRNA-30a prevents puromycin aminonucleoside-induced podocytic apoptosis by upregulating the glucocorticoid receptor α. Mol Med Rep. 2015 Oct;12(4):6043-52. doi: 10.3892/mmr.2015.4226. PubMed PMID: 26299668.
10: Pawluczyk IZ, Najafabadi MG, Brown JR, Bevington A, Topham PS. Sialic acid supplementation ameliorates puromycin aminonucleoside nephrosis in rats. Lab Invest. 2015 Sep;95(9):1019-28. doi: 10.1038/labinvest.2015.78. PubMed PMID: 26121320.
11: Axelsson J, Rippe A, Rippe B. mTOR inhibition with temsirolimus causes acute increases in glomerular permeability, but inhibits the dynamic permeability actions of puromycin aminonucleoside. Am J Physiol Renal Physiol. 2015 May 15;308(10):F1056-64. doi: 10.1152/ajprenal.00632.2014. PubMed PMID: 25740597.
12: Zennaro C, Rastaldi MP, Pascolo L, Stebel M, Trevisan E, Artero M, Tiribelli C, Di Maso V, Carraro M. Podocyte expression of membrane transporters involved in puromycin aminonucleoside-mediated injury. PLoS One. 2013 Jun 20;8(6):e66159. doi: 10.1371/journal.pone.0066159. PubMed PMID: 23840417; PubMed Central PMCID: PMC3688733.
13: Suzuki K, Fukusumi Y, Yamazaki M, Kaneko H, Tsuruga K, Tanaka H, Ito E, Matsui K, Kawachi H. Alteration in the podoplanin-ezrin-cytoskeleton linkage is an important initiation event of the podocyte injury in puromycin aminonucleoside nephropathy, a mimic of minimal change nephrotic syndrome. Cell Tissue Res. 2015 Oct;362(1):201-13. doi: 10.1007/s00441-015-2178-8. PubMed PMID: 25920588.
14: Takahashi A, Fukusumi Y, Yamazaki M, Kayaba M, Kitazawa Y, Tomita M, Kawachi H. Angiotensin II type 1 receptor blockade ameliorates proteinuria in puromycin aminonucleoside nephropathy by inhibiting the reduction of NEPH1 and nephrin. J Nephrol. 2014 Dec;27(6):627-34. doi: 10.1007/s40620-014-0147-z. PubMed PMID: 25298195.
15: Wang L, Zhu J, Fang M, Zhang T, Xie H, Wang N, Shen N, Guo H, Fu B, Lin H. Inhibition of p53 deSUMOylation exacerbates puromycin aminonucleoside-induced apoptosis in podocytes. Int J Mol Sci. 2014 Nov 18;15(11):21314-30. doi: 10.3390/ijms151121314. PubMed PMID: 25411797; PubMed Central PMCID: PMC4264227.
16: Kang YL, Saleem MA, Chan KW, Yung BY, Law HK. Trehalose, an mTOR independent autophagy inducer, alleviates human podocyte injury after puromycin aminonucleoside treatment. PLoS One. 2014 Nov 20;9(11):e113520. doi: 10.1371/journal.pone.0113520. PubMed PMID: 25412249; PubMed Central PMCID: PMC4239098.
17: Wen Y, Zhan Y, Liu H, Zhao T, Yang L, Zhang H, Dong X, Li P. Yi Qi Qing Re Gao formula ameliorates puromycin aminonucleoside-induced nephrosis by suppressing inflammation and apoptosis. BMC Complement Altern Med. 2015 May 27;15:155. doi: 10.1186/s12906-015-0673-9. PubMed PMID: 26014479; PubMed Central PMCID: PMC4443657.
18: Li X, Zhang X, Li X, Ding F, Ding J. The role of survivin in podocyte injury induced by puromycin aminonucleoside. Int J Mol Sci. 2014 Apr 17;15(4):6657-73. doi: 10.3390/ijms15046657. PubMed PMID: 24747598; PubMed Central PMCID: PMC4013653.
19: Yamashita J, Nakajima K, Ohno Y, Kaneshiro Y, Matsuo T, Tanaka H, Kaneko K. Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats. Eur J Pharmacol. 2008 Jul 28;589(1-3):239-44. doi: 10.1016/j.ejphar.2008.04.065. PubMed PMID: 18541230.
20: Yu SY, Qi R. Role of bad in podocyte apoptosis induced by puromycin aminonucleoside. Transplant Proc. 2013 Mar;45(2):569-73. doi: 10.1016/j.transproceed.2012.07.160. PubMed PMID: 23498794.
